文献速递冠心病

EURO-ENDO评分预测左侧感染性心内膜炎30天死亡率

European Infective Endocarditis (EURO-ENDO) score for predicting 30-day mortality in left-sided infective endocarditis.
PubMed 文献 · Heart · 2026-09-18

基于ESC-EURO-ENDO前瞻性多中心注册研究2171例左侧感染性心内膜炎患者,开发并外部验证了包含11个变量的EURO-ENDO风险评分,用于预测30天死亡率。模型内部验证AUROC 0.763,外部验证队列(377例)AUROC 0.799(95%CI 0.730-0.868),校准良好,可辅助早期风险分层和多学科决策。

要点

  • EURO-ENDO评分含11个初始评估即可获得的变量,预测左侧感染性心内膜炎30天死亡。
  • 注册队列30天死亡率11.9%,外部验证队列12.7%,模型区分度和校准度均良好。
  • 评分工具或有助于早期风险分层、心内膜炎团队讨论及临床决策。

核心结论

  • EURO-ENDO风险评分可准确预测左侧感染性心内膜炎患者个体化30天死亡率,内部和外部验证表现一致。

研究设计与样本

  • 研究基于ESC-EURO-ENDO前瞻性多中心注册研究,纳入2171例按ESC 2015标准诊断的左侧感染性心内膜炎患者,最终分析2140例。
  • 采用多变量逻辑回归开发模型,内部验证用bootstrap重采样,外部验证在西班牙巴塞罗那两家三级中心2019-2024年连续377例患者中完成。

主要发现

  • 注册队列中254例(11.9%)在30天内死亡,外部验证队列中48/377例(12.7%)死亡。
  • 模型内部验证AUROC 0.763,Hosmer-Lemeshow p=0.825,Brier评分0.09。
  • 外部验证AUROC 0.799(95%CI 0.730-0.868),校准斜率1.017,预期与观察比值1.124。

关键数值与推荐

  • 11个独立预测变量包括:既往卒中或TIA、既往心脏手术、心力衰竭或心源性休克、肌酐>2 mg/dL、赘生物>10 mm、重度反流、脓肿、血培养阴性、金黄色葡萄球菌感染、无手术指征、有手术指征但无手术意图。

临床怎么用

  • 该评分可在初始诊断评估阶段用于左侧感染性心内膜炎患者的早期风险分层。
  • 评分结果可支持多学科心内膜炎团队讨论和临床决策,包括手术风险评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: A major challenge in managing left-sided infective endocarditis (LSIE) is identifying patients who will benefit from surgery including those with prohibitive operative risk. However, no widely validated models are currently available to estimate 30-day mortality early after the initial diagnostic evaluation in the broader LSIE population including patients managed without surgery. We aimed to develop and externally validate the European Infective Endocarditis (EURO-ENDO) risk score for predicting 30-day mortality in patients with LSIE. METHODS: The prospective, multicentre European Society of Cardiology (ESC)-EURObservational Research Programme EURO-ENDO registry included 2171 patients with LSIE diagnosed according to ESC 2015 criteria. Clinical, biological, microbiological and imaging variables were analysed and a multivariable logistic regression model was developed. Internal validation was performed using bootstrap resampling. External validation was conducted in an independent temporal cohort of 377 consecutive patients with LSIE from two tertiary centres in Barcelona, Spain, recruited between 2019 and 2024. RESULTS: Among 2140 registry patients included in the final analysis, 254 (11.9%) died within 30 days. Eleven variables were independently associated with 30-day mortality and included in the EURO-ENDO prediction model: previous stroke or transient ischaemic attack, previous cardiac surgery, heart failure or cardiogenic shock, creatinine >2 mg/dL, vegetations >10 mm, severe regurgitation, abscess, negative blood cultures, Staphylococcus aureus infection, absence of surgical indication and surgical indication without intention to operate. The model showed good discrimination and calibration (area under the receiver operating characteristic (AUROC) 0.763; Hosmer-Lemeshow p=0.825; Brier score 0.09). In the external validation cohort, 48/377 patients (12.7%) died; discrimination remained excellent (AUROC 0.799; 95% CI 0.730 to 0.868) with good calibration (slope 1.017; expected-to-observed ratio 1.124). CONCLUSIONS: The EURO-ENDO risk score, incorporating 11 variables available during the initial diagnostic evaluation, accurately predicts individualised 30-day mortality in patients with LSIE and showed consistent performance in both internal and external validation cohorts. This tool may support early risk stratification, multidisciplinary endocarditis team discussions and clinical decision-making (https://scoreei.web.app/score).

来源:Heart,查看原文。版权归原作者所有。

引用

  1. Sambola, Lozano-Torres, Boersma, et al. European Infective Endocarditis (EURO-ENDO) score for predicting 30-day mortality in left-sided infective endocarditis. Heart. 2026. PMID: 42760106. doi:10.1136/heartjnl-2026-328064

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。